Advertisement
U.S. markets closed

KalVista Pharmaceuticals, Inc. (KALV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
10.15+0.82 (+8.85%)
At close: 04:00PM EST
10.15 0.00 (0.00%)
After hours: 04:02PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close9.32
Open9.39
Bid10.11 x 100
Ask10.20 x 100
Day's Range9.32 - 10.22
52 Week Range7.39 - 16.88
Volume405,001
Avg. Volume405,367
Market Cap499.537M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-3.57
Earnings DateDec 05, 2024 - Dec 09, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.17
  • Business Wire

    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass. & SALISBURY, England, November 12, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences:

  • TipRanks

    KalVista Secures $184M Financing for Sebetralstat Launch

    KalVista Pharmaceuticals ( (KALV) ) has provided an update. KalVista Pharmaceuticals has secured a significant up to $184 million synthetic royalty financing deal with DRI Healthcare Trust to fund the commercialization of sebetralstat, a novel oral therapy for hereditary angioedema (HAE). The agreement includes an initial $100 million upfront payment, potential milestone payments, and a tiered royalty structure based on global net sales. This strategic move strengthens KalVista’s financial posit